CNIO team describes the 'energy engine' of a protein that mediates key processes in cancer cells

May 01, 2019

Proteins are sometimes described as the building blocks of life; inside cells proteins associate into large macromolecular complexes, consortiums of proteins that cooperate to perform specific functions. A large number of cancer research studies focus on finding inhibitors for some of these protein complexes. Kinases like mTOR and ATR, and enzymes like telomerase, which are overexpressed in tumours, are among such complexes. There are proteins (called chaperones and co-chaperones) whose function is to actually build these protein complexes within cells and the inhibition of this assembly process is being studied as an anti-cancer strategy. Kinases and enzymes like mTOR, ATR or telomerase can be compared to a building under construction, and chaperones (like HSP90) and co-chaperones (like R2TP) would be construction machines. Current evidence suggests the therapeutic potential of targeting RUVBL1-RUVBL2, the energy engine in the co-chaperone R2TP, in the treatment of cancer. This has led researchers from the Macromolecular Complexes in DNA Damage Response Group at the Spanish National Cancer Research Centre (CNIO) to use the powerful tool of cryo-electron microscopy to determine the mechanism regulating RUVBL1 and RUVBL2. The study has been published in Science Advances.

As previously reported, the Macromolecular Complexes in DNA Damage Response Group had used cryo-electron microscopy to determine the high-resolution structure of R2TP. In the study, researchers at CNIO observed how R2TP is designed to place the chaperone HSP90 in contact with the proteins it would act on. The R2TP complex has an energy engine, a ring formed by ATPases RUVBL1 and RUVBL2, which uses the energy released from the hydrolysis of ATP into ADP. In this energy production mechanism, ATPases capture ATP in the cell and continuously release ADP as waste and energy. Scientists found that in the ring formed by RUVBL1 and RUVBL2, access to the ATP binding site was completely blocked, holding ATP or ADP inside and thus preventing the exchange of energy and the motor from working. The question is, how can the energy required to assemble protein complexes be used?

The answer was found by observing the R2TP system under the cryo-electron microscope: "We identified a region in RUVBL2 that acts as a gate that controls the access of ATP and ADP to the protein; a requirement to use the energy provided by ATP," explains Óscar Llorca, Head of the Macromolecular Complexes in DNA Damage Response Group at CNIO. "The key that regulates the opening of this gate is the interaction between the ATPase RUVBL2 and a component of R2TP required for mTOR assembly."

Studying the structure and dynamics of proteins, that is, understanding the interactions between proteins that are necessary for biological functions, has always been very challenging, in terms of both experimental observations and computational approaches. However, the use of cryo-electron microscopy in the study of proteins and macromolecular complexes, one of the priorities of the Structural Biology Programme at CNIO, is revolutionising the way we observe and understand how proteins work, as mentioned in Nature a few months back.

A full understanding of the processes determining how macromolecular complexes are built can help to find novel cancer treatment strategies based on inhibiting protein assembly. Several studies have shown that the inhibition of the RUVBL1-RUVBL2 ATPases has therapeutic potential in the treatment of cancer. The recent study conducted by the team led by Llorca at CNIO, in collaboration with the group of Laurence H. Pearl at the University of Sussex (UK), and published in Science Advances will help accelerate progress in this field.

"We know that the energy from ATP is used by RUVBL1 and RUVBL2 ATPases in the assembly of mTOR and other macromolecular complexes. But we do not know how the energy is used and what it is used for," says Llorca. "In this study, we found that RUVBL2 has a gate that regulates the access of ATP to the catalytic site where the energy is released. We also observed that the opening of the gate is regulated by molecules that are needed in the assembly of mTOR, thus coupling the motor activation to the moment when the energy is required. However, we do not know what this energy is used for exactly at the molecular level, which needs further studies."
The study has been funded by the Ministry of Science, Innovation and Universities, the National Institute of Health Carlos III, the European Regional Development Fund and Wellcome Trust.

Reference article:Structural mechanism for regulation of the AAA-ATPases RUVBL1-RUVBL2 in the R2TP co-chaperone revealed by cryo-EM. Hugo Muñoz-Hernández, Mohinder Pal, Carlos F. Rodríguez, Rafael Fernández-Leiro, Chrisostomos Prodromou, Laurence H. Pearl, Oscar Llorca (Science Advances, 2019). DOI:

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to